1 day Ago By ABMN Staff
Solid Biosciences Inc. ( NASDAQ:SLDB – Get Free Report ) has been assigned a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $15.67. SLDB has been the topic of several analyst reports.
Barclays dropped their target price on Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th.
HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a report on Wednesday, August 14th. JPMorgan Chase & Co.
raised shares of Solid Biosciences from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $15.00 in a research note on Monday, July 15th.
William Blair raised shares of Solid Biosciences to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $20.00 target price on shares of Solid Biosciences in a research report on Friday, June 21st.
View Our Latest Stock Report on SLDB Hedge Funds Weigh In On Solid Biosciences Solid Biosciences Stock Down 3.3 % Shares of SLDB stock opened at $7.14 on Thursday.
Solid Biosciences has a fifty-two week low of $1.81 and a fifty-two week high of $15.05.
The firm’s 50 day moving average price is $8.47 and its two-hundred day moving average price is $9.08.
The stock has a market cap of $274.03 million, a price-to-earnings ratio of -1.81 and a beta of 1.
92. Solid Biosciences ( NASDAQ:SLDB – Get Free Report ) last posted its earnings results on Tuesday, August 13th. The company reported ($0.
61) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.05.
On average, equities analysts forecast that Solid Biosciences will post -2.61 EPS for the current fiscal year. About Solid Biosciences ( Get Free Report Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States.
The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. See Also Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
